These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 8109918)
1. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Huband MD; Cohen MA; Meservey MA; Roland GE; Yoder SL; Dazer ME; Domagala JM Antimicrob Agents Chemother; 1993 Dec; 37(12):2563-70. PubMed ID: 8109918 [TBL] [Abstract][Full Text] [Related]
2. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Domagala JM; Heifetz CL Antimicrob Agents Chemother; 1991 Jan; 35(1):141-6. PubMed ID: 2014970 [TBL] [Abstract][Full Text] [Related]
3. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. Hoogkamp-Korstanje JA J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498 [TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564 [TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics. Chin NX; Neu HC J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856 [TBL] [Abstract][Full Text] [Related]
6. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Cohen MA; Huband MD; Mailloux GB; Yoder SL; Roland GE; Heifetz CL Diagn Microbiol Infect Dis; 1991; 14(3):245-58. PubMed ID: 1889177 [TBL] [Abstract][Full Text] [Related]
7. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Nilius AM; Shen LL; Hensey-Rudloff D; Almer LS; Beyer JM; Balli DJ; Cai Y; Flamm RK Antimicrob Agents Chemother; 2003 Oct; 47(10):3260-9. PubMed ID: 14506039 [TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of PD 131628, a new quinolone antimicrobial agent. Cooper MA; Andrews JM; Wise R J Antimicrob Chemother; 1992 May; 29(5):519-27. PubMed ID: 1320603 [TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro potency of gemifloxacin and fluoroquinolones against recent European clinical isolates from a global surveillance study. Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA; Eur J Clin Microbiol Infect Dis; 2001 Nov; 20(11):814-9. PubMed ID: 11783700 [TBL] [Abstract][Full Text] [Related]
11. The comparative in-vitro activity of eight newer quinolones and nalidixic acid. King A; Phillips I J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100 [TBL] [Abstract][Full Text] [Related]
12. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds. Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615 [TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo antibacterial activities of T-3761, a new quinolone derivative. Fukuoka Y; Ikeda Y; Yamashiro Y; Takahata M; Todo Y; Narita H Antimicrob Agents Chemother; 1993 Mar; 37(3):384-92. PubMed ID: 8460909 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone. Neu HC; Chin NX Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029 [TBL] [Abstract][Full Text] [Related]
15. In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. Rolston KV; Ho DH; LeBlanc B; Streeter H; Dvorak T J Antimicrob Chemother; 1997 Jun; 39 Suppl B():15-22. PubMed ID: 9222065 [TBL] [Abstract][Full Text] [Related]
16. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones. Wise R; Brenwald NP; Andrews JM; Boswell F J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816 [TBL] [Abstract][Full Text] [Related]
17. In vitro activities of BAY Y3118, ciprofloxacin, ofloxacin, and fleroxacin against gram-positive and gram-negative pathogens from respiratory tract and soft tissue infections. Bongaerts GP; Hoogkamp-Korstanje JA Antimicrob Agents Chemother; 1993 Sep; 37(9):2017-9. PubMed ID: 8239624 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups. Huband MD; Cohen MA; Zurack M; Hanna DL; Skerlos LA; Sulavik MC; Gibson GW; Gage JW; Ellsworth E; Stier MA; Gracheck SJ Antimicrob Agents Chemother; 2007 Apr; 51(4):1191-201. PubMed ID: 17261623 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of the new fluoroquinolone CP-99,219. Neu HC; Chin NX Antimicrob Agents Chemother; 1994 Nov; 38(11):2615-22. PubMed ID: 7872757 [TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Hosaka M; Yasue T; Fukuda H; Tomizawa H; Aoyama H; Hirai K Antimicrob Agents Chemother; 1992 Oct; 36(10):2108-17. PubMed ID: 1332587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]